Can-Fite BioPharma
About Science Pipeline Investor Information Contact Us

Investor Information

Investor Information

Investor Information

Company Information

Can-Fite BioPharma Ltd. (NYSE American: CANF)

Can-Fite BioPharma Ltd. is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and  psoriasis. Can-Fite's liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies.  These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date.

Stock Information

Last Change Volume

Can-Fite's ADRs trade in the USA under the ticker CANF and the ordinary shares trade on the Tel-Aviv Stock Exchange under the ticker CFBI.

More on CFBI »

Investor Relations

(800) 716-4880

Quick Links

Recent News

Upcoming Event

Nov 30 2020 9:15 am ET

Third Quarter 2020 Financial Results & Clinical Update Conference Call

November 30, 2020 at 9:15 am ET

Dial-in U.S.: 1-877-423-9813
Dial-in Israel: 1-201-689-8573
Conference ID: 13713545

Related Documents & Materials